Filtered By:
Condition: Atrial Fibrillation
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 241 results found since Jan 2013.

Incidence and Prediction of Ischemic Stroke among Atrial Fibrillation Patients with End-Stage Renal Disease Requiring Dialysis
Source: Heart Rhythm - June 18, 2014 Category: Cardiology Authors: Tze-Fan Chao, Chia-Jen Liu, Kang-Ling Wang, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Ta-Chuan Tuan, Fa-Po Chung, Jo-Nan Liao, Tzeng-Ji Chen, Gregory Y.H. Lip, Shih-Ann Chen Source Type: research

Perioperative Aspirin and Clonidine and Risk of Acute Kidney Injury
In this sub-study of the POISE-2 study, neither ASA or clonidine reduced the risk of acute kidney injury after non-cardiac surgery. Of note, aspirin increased the risk of major bleeding (which was associated with a greater risk of acute kidney injury).  As well, clonidine increased the risk of clinically important hypotension (which was associated with a greater risk of acute kidney injury). : Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease Risk of acute kidney injury associated with the use of fluoroquinolones Chronic Dialysis and Death Among Survivors of Acute Kidney Injury Requiring Dialysis
Source: Nephrology Now - November 16, 2014 Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Acute Kidney Injury Source Type: research

Preoperative atrial fibrillation and outcome in patients undergoing on-pump or off-pump coronary bypass surgery: lessons learned from the GOPCABE trial
CONCLUSIONS AF at admission is a significant risk factor for elderly patients undergoing coronary bypass grafting. However, this risk is not altered by performing bypass grafting off pump.
Source: Interactive CardioVascular and Thoracic Surgery - December 18, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Boning, A., Diegeler, A., Hilker, M., Zacher, M., Reents, W., Faerber, G., Doenst, T., for the GOPCABE investigators Tags: Molecular biology, Myocardial infarction, Myocardial protection, Transplantation - heart Adult Cardiac Source Type: research

Does concomitant tricuspid annuloplasty increase perioperative mortality and morbidity when correcting left-sided valve disease?
In conclusion, there is good evidence to support that tricuspid annuloplasty is a low-risk procedure and concomitant TV repair does not significantly increase the perioperative mortality and morbidity when correcting left-sided valve disease.
Source: Interactive CardioVascular and Thoracic Surgery - December 18, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Zhu, T.-Y., Wang, J.-G., Meng, X. Tags: Basic research vascular Adult Cardiac Source Type: research

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
In conclusion, based on these single-dose PK data, a supplementary dose of edoxaban may not be required following a haemodialysis session. Importantly, haemodialysis is not an effective mechanism for removal of edoxaban from the blood. PMID: 25566930 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 8, 2015 Category: Hematology Authors: Parasrampuria DA, Marbury T, Matsushima N, Chen S, Wickremasingha PK, He L, Dishy V, Brown KS Tags: Thromb Haemost Source Type: research

Management of Bleeding Complications in Patients Taking Direct Oral Anticoagulants at a Large Tertiary Academic Medical Center
Abstract Direct oral anticoagulants (DOACs) offer a fixed-dose alternative to warfarin for stroke prevention in patients with atrial fibrillation. However, there is minimal evidence to guide the management of bleeding in patients taking a DOAC. We retrospectively evaluated the acute management of major bleeding in this patient population at a large, tertiary academic medical center. We evaluated various strategies of management including dialysis, transfusions, pharmacologic agents, surgical intervention, and reinitiation of anticoagulation. We also assessed length of intensive care unit and hospital stay, mor...
Source: Current Emergency and Hospital Medicine Reports - June 13, 2015 Category: Emergency Medicine Source Type: research

Dose-Finding Study of Rivaroxaban in Hemodialysis Patients
Conclusions A 10-mg dose of rivaroxaban in hemodialysis patients without residual kidney function results in drug exposure similar as published for 20mg in healthy volunteers. Rivaroxaban is not eliminated by dialysis. There is no accumulation after multiple daily dosing. The efficacy and safety of rivaroxaban in hemodialysis patients should be the subject of a large randomized trial.
Source: American Journal of Kidney Diseases - June 22, 2015 Category: Urology & Nephrology Source Type: research

Challenging the use of warfarin in patients on dialysis with atrial fibrillation
Nature Reviews Nephrology 11, 450 (2015). doi:10.1038/nrneph.2015.87 Authors: Georg Schlieper & Jürgen Floege We read with great interest the article from Qamar and Bhatt (Anticoagulation therapy: Balancing the risks of stroke and bleeding in CKD. Nat. Rev. Nephrol.11, 200–202; 2015) that discussed the observational study by Bonde et al. on anticoagulation
Source: Nature Reviews Nephrology - July 7, 2015 Category: Urology & Nephrology Authors: Georg SchlieperJürgen Floege Tags: Correspondence Source Type: research

Clinical Benefit of Warfarin in Dialysis Patients With Atrial Fibrillation
Patients with atrial fibrillation (AF) and end-stage chronic kidney disease (CKD) receiving dialysis are at higher risk of stroke (1). Warfarin has been shown to reduce the frequency of strokes by 64.0% in patients with AF; however, its use in dialysis patients has not received consensus owing to the lack of randomized controlled trial data and associated increased bleeding risk.
Source: Journal of the American College of Cardiology - September 7, 2015 Category: Cardiology Source Type: research

Dabigatran treatment simulation in patients undergoing maintenance haemodialysis.
This study simulated the dose-exposure relationship of dabigatran in patients undergoing haemodialysis. Dabigatran exposure was modelled at once- and twice-daily doses of 75 mg, 110 mg and 150 mg and at variations in non-renal clearance and dialysis settings. Resultant dose exposure (area under the curve [AUC]) was compared with values simulated from typical patients in the RE-LY® trial (based on a previously characterised pharmacometric model). In this simulation, all twice-daily dosages resulted in exposures above those simulated from typical RE-LY patients (1.5- to 3.3-fold increase in AUC) and thus may not be optimal ...
Source: Thrombosis and Haemostasis - October 15, 2015 Category: Hematology Authors: Liesenfeld KH, Clemens A, Kreuzer J, Brueckmann M, Schulze F Tags: Thromb Haemost Source Type: research

Safety of warfarin therapy in chronic hemodialysis patients: a prospective cohort study
Conclusion The results of this study suggested that warfarin use by HD patients might not be harmful in chronic state, while the safety for the initiation of warfarin therapy in HD patients remained to be determined.
Source: Clinical and Experimental Nephrology - December 1, 2015 Category: Urology & Nephrology Source Type: research

The Effect of Cardiopulmonary Bypass on Dabigatran Levels
DABIGATRAN IS a novel anticoagulant that is licensed for use for the prevention of stroke in the presence of atrial fibrillation. Its use has expanded rapidly in New Zealand, primarily due to there being no requirement for routine monitoring of its effect, as there is for warfarin. There are case reports in the literature describing management of patients coming for urgent cardiac surgery, which revolve mainly around the use of dialysis and massive transfusion of clotting factors to manage the bleeding associated with surgery.
Source: Journal of Cardiothoracic and Vascular Anesthesia - December 31, 2015 Category: Anesthesiology Authors: Kelly Byrne Tags: CASE REPORT Source Type: research

Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study
Background: Stroke prevention in dialysis-dependent patients with atrial fibrillation (AF) is an unresolved clinical dilemma. Indeed, no randomized controlled trial evaluating the efficacy and safety of oral anticoagulants in this population, has been conducted so far. Observational research on the use of warfarin in patients on dialysis has shown conflicting results. This uncertainty is mirrored by the wide variations in warfarin prescription patterns across centers. We sought to evaluate the association between the use of vitamin K antagonists (VKAs) and mortality among hemodialysis patient with AF and to assess potentia...
Source: American Journal of Nephrology - September 6, 2016 Category: Neurology Source Type: research

Antiplatelet agents in hemodialysis.
In conclusion, since CRF patients are one of the groups at highest risk for atherosclerotic events, it could be reasonable to use aspirin in HD patients. However, the bleeding risk in HD patients needs to be strongly evaluated, especially before starting dual AA treatment. PMID: 27928736 [PubMed - as supplied by publisher]
Source: Journal of Nephrology - December 7, 2016 Category: Urology & Nephrology Authors: Migliori M, Cantaluppi V, Scatena A, Panichi V Tags: J Nephrol Source Type: research